Search Results for "Pain"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pain. Results 141 to 150 of 279 total matches.
Atogepant (Qulipta) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021 (Issue 1636)
the onset of menses.3
MECHANISM OF ACTION — CGRP is a potent
vasodilator and pain-signaling ...
Atogepant (Qulipta – Abbvie), an oral small-molecule
calcitonin gene-related peptide (CGRP) receptor
antagonist ("gepant"), has been approved by the
FDA for prevention of episodic migraine in adults. It
is the second oral CGRP receptor antagonist to be
approved in the US for this indication; the first was
rimegepant (Nurtec ODT), which is also approved
for acute treatment of migraine. Parenteral CGRP
monoclonal antibodies are approved for prevention
of migraine (see Table 3).
Comparison Table: Drugs for Alzheimer's Disease (online only)
The Medical Letter on Drugs and Therapeutics • Aug 22, 2022 (Issue 1657)
pruritus,
dermatitis and pain, muscle
spasms, insomnia, abdominal
pain, constipation, diarrhea ...
View the Comparison Table: Drugs for Alzheimer's Disease
In Brief: RSV Vaccine (Arexvy) for Ages 50-59
The Medical Letter on Drugs and Therapeutics • Jul 22, 2024 (Issue 1707)
years old within 4 days of receiving Arexvy were injection-site pain (75.8%), erythema (13.2 ...
The recombinant respiratory syncytial virus (RSV)
vaccine Arexvy (GSK) has now received FDA
approval for use in adults 50-59 years old who
are at increased risk for lower respiratory tract
disease (LRTD) caused by RSV. It was previously
approved only for adults ≥60 years old. Two other
RSV vaccines have received FDA approval: Abrysvo,
a recombinant vaccine that is licensed for use in
adults ≥60 years old and in pregnant women at
32-36 weeks' gestation to prevent RSV-associated
LRTD in their infants, and mResvia, an mRNA vaccine
recently licensed for use in adults ≥60 years old...
Med Lett Drugs Ther. 2024 Jul 22;66(1707):113-4 doi:10.58347/tml.2024.1707a | Show Introduction Hide Introduction
Vadadustat (Vafseo) for Anemia of Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025 (Issue 1722)
, headache, nausea, fatigue,
abdominal pain, vomiting, GI erosion, dizziness,
dyspnea, arteriovenous ...
The FDA has approved the hypoxia-inducible factor
prolyl hydroxylase inhibitor (HIF-PHI) vadadustat
(Vafseo – Akebia) for oral treatment of anemia due
to chronic kidney disease (CKD) in adults who have
been on dialysis for at least 3 months. Vadadustat is
the second HIF-PHI to be approved in the US for this
indication; daprodustat (Jesduvroq) was approved
earlier, but it was withdrawn from the US market in
2024 for commercial reasons.
Med Lett Drugs Ther. 2025 Feb 17;67(1722):27-9 doi:10.58347/tml.2025.1722b | Show Introduction Hide Introduction
Mirikizumab (Omvoh) — An IL-23 Antagonist for Crohn's Disease
The Medical Letter on Drugs and Therapeutics • May 12, 2025 (Issue 1728)
to
achieve a clinical response (a ≥30% decrease in stool frequency or
abdominal pain) at week 12 ...
The injectable interleukin (IL)-23 antagonist
mirikizumab-mrkz (Omvoh – Lilly) is now FDA-approved
for treatment of moderately to severely active Crohn's
disease (CD) in adults. Mirikizumab was approved in
2023 for treatment of ulcerative colitis. Two other IL-23 antagonists, risankizumab (Skyrizi) and guselkumab
(Tremfya), are also approved for treatment of CD.
Med Lett Drugs Ther. 2025 May 12;67(1728):78-80 doi:10.58347/tml.2025.1728d | Show Introduction Hide Introduction
Lurbinectedin (Zepzelca) for Small-Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
,
decreased appetite, musculoskeletal pain, decreased
albumin, constipation, dyspnea, decreased sodium ...
The alkylating agent lurbinectedin (Zepzelca – Jazz)
has received accelerated approval from the FDA
for treatment of metastatic small-cell lung cancer
(SCLC) in adults with disease progression on or after
platinum-based chemotherapy. Accelerated approval
was based on the overall response rate and duration
of response. About 13-15% of lung cancers are small-cell
cancers. Most SCLCs occur in patients who are
current or former smokers.
Capmatinib (Tabrecta) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
EFFECTS — Capmatinib can cause edema,
musculoskeletal pain, fatigue, vomiting, dyspnea,
cough ...
The FDA has granted regular approval to the oral
kinase inhibitor capmatinib (Tabrecta – Novartis) for
treatment of metastatic non-small cell lung cancer
(NSCLC) in adults whose tumors have a mutation that
leads to mesenchymal-epithelial transition (MET)
exon 14 skipping. MET exon 14 skipping mutations
occur in 3-4% of NSCLC cases. The drug received
accelerated approval for the same indication in 2020
based on initial overall response rates and duration
of response.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e65-6 doi:10.58347/tml.2023.1674d | Show Introduction Hide Introduction
Phosphodiesterase-5 Inhibitors for Alzheimer's Disease?
The Medical Letter on Drugs and Therapeutics • Oct 31, 2022 (Issue 1662)
, rhinitis, and dyspepsia. Priapism and low
back pain can also occur. Acute hearing loss, with
or without ...
A reader asked us to review use of the
phosphodiesterase-5 (PDE5) inhibitor sildenafil for
treatment of Alzheimer's disease (AD).
In Brief: A New Prostate Cancer Indication for Olaparib (Lynparza) (online only)
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
, lymphopenia, dizziness, and abdominal pain
were also reported.
DRUG INTERACTIONS — Olaparib is metabolized ...
The oral poly(ADP-ribose) polymerase (PARP)
inhibitor olaparib (Lynparza – AstraZeneca) has now
been approved by the FDA for use in combination
with abiraterone (Zytiga, and others) and either
prednisone or prednisolone for treatment of adults
with deleterious or suspected deleterious BRCA-mutated
(BRCAm) metastatic castration-resistant
prostate cancer (mCRPC). Olaparib was previously
approved by the FDA for treatment of adults with
deleterious or suspected deleterious germline or
somatic homologous recombinant repair (HRR) genemutated
mCRPC who progressed on prior treatment
with...
Med Lett Drugs Ther. 2023 Jun 26;65(1679):e106-7 doi:10.58347/tml.2023.1679g | Show Introduction Hide Introduction
Osimertinib (Tagrisso) for Adjuvant Treatment of NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
EFFECTS — Diarrhea, rash, musculoskeletal
pain, dry skin, stomatitis, fatigue, and cough are
common ...
The FDA has approved osimertinib (Tagrisso –
AstraZeneca), an oral kinase inhibitor, for adjuvant
treatment of non-small cell lung cancer (NSCLC)
after tumor resection in adults who have epidermal
growth factor receptor (EGFR) exon 19 deletions or
exon 21 L858R mutations. Osimertinib is the first
targeted therapy to be approved in the US for this
indication. The drug was previously approved for
first-line treatment of adults with NSCLC with EGFR
exon 19 deletions or exon 21 L858R mutations and for
treatment of EGFR T790M mutation-positive NSCLC
in adults whose disease progressed...
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e131-2 doi:10.58347/tml.2023.1682c | Show Introduction Hide Introduction